ADAP - Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Optionskæde

Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
US ˙ NasdaqCM ˙ US00653A1079
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

Udløb
Calls for markedsdato October 27, 2025
Kontrakt Strejke Bud Spørg Sidst Bind HEJ IV Delta Gamma Theta Vega Rho
ADAP20260618C00000500 0.50 0.00 0.05 0.04 56 5,260 67.64% 1.00 63.73 -0.00 0.00 0.00
ADAP20260618C00001000 1.00 0.00 0.30 0.00 0 125 245.96% 1.00 18.10 -0.00 0.00 0.00
ADAP20260618C00001500 1.50 0.00 0.05 0.05 50 81 137.48% 1.00 25.33 -0.00 0.00 0.00
ADAP20260618C00002000 2.00 0.00 1.00 0.00 0 2 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618C00002500 2.50 0.00 0.75 0.00 0 4 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618C00005000 5.00 0.00 0.05 0.00 0 50 195.79% 0.97 15.90 -0.00 0.00 0.00
ADAP20260618C00007500 7.50 0.00 0.05 0.00 0 83 213.20% 0.94 14.22 -0.00 0.00 0.00
Puts for markedsdato October 27, 2025
Kontrakt Strejke Bud Spørg Sidst Bind HEJ IV Delta Gamma Theta Vega Rho
ADAP20260618P00000500 0.50 0.25 0.50 0.00 0 6 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00001000 1.00 0.45 1.00 0.00 0 1 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00001500 1.50 0.95 1.50 0.00 0 0 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00002000 2.00 1.45 2.00 0.00 0 0 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00002500 2.50 2.05 2.50 0.00 0 0 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00005000 5.00 4.30 5.00 0.00 0 0 0.00% 0.00 0.00 0.00 0.00 0.00
ADAP20260618P00007500 7.50 6.70 7.50 0.00 0 0 0.00% 0.00 0.00 0.00 0.00 0.00
Other Listings
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista